Titre
Clinical experience with adalimumab in a multicenter Swiss cohort of patients with Crohn's disease.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Nichita, Cristina
Auteure/Auteur
Stelle, Marc
Auteure/Auteur
Vavricka, Stephan
Auteure/Auteur
Ali Abdou, El-Wafa
Auteure/Auteur
Ballabeni, Pierluigi
Auteure/Auteur
de Saussure, Philippe
Auteure/Auteur
Straumann, Alex
Auteure/Auteur
Rogler, Gerhard
Auteure/Auteur
Michetti, Pierre
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
1421-9867[electronic], 0012-2823[linking]
Statut éditorial
Publié
Date de publication
2010
Volume
81
Numéro
2
Première page
78
Dernière page/numéro d’article
85
Peer-reviewed
Oui
Langue
anglais
Résumé
BACKGROUND: Controlled clinical trials have demonstrated the efficacy and safety of adalimumab in patients with moderate-to-severe Crohn's disease (CD), but there is, however, only limited long-term experience with adalimumab in daily practice. AIM: To assess the long-term effectiveness and safety of adalimumab in a multicenter cohort of practice-based patients with moderate-to-severe CD. METHODS: We retrospectively reviewed the charts of CD patients who received adalimumab over a 3-year period. Disease severity was scored using the Harvey-Bradshaw index (HBI). Remission was defined as an HBI of <or=4 and response as a reduction in the HBI of >3 points at evaluation compared to the baseline. Univariate logistic regression analysis was used to identify the predictive variables associated with response. RESULTS: The charts of 55 patients were reviewed; remission and response rates observed at weeks 4-6 were 52.7 and 83.6%, respectively. Remission was maintained at weeks 12, 24 and 52 in 89.6, 72.4 and 44.7% of patients, respectively. Remission and response rates were not influenced by smoking status, disease location or duration, the first month total dose, or previous infliximab therapy. The remission rate at weeks 4-6 was significantly higher in patients intolerant of infliximab as compared to those who lost response to this drug. Adalimumab was well tolerated overall. CONCLUSION: Adalimumab can be considered a suitable option in patients with moderate-to-severe CD, demonstrating sustained long-term effectiveness.
PID Serval
serval:BIB_94852A3F6D80
PMID
Date de création
2010-02-24T10:18:25.127Z
Date de création dans IRIS
2025-05-21T00:08:39Z